TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19

SGT-53 is a novel investigational agent that comprises an immunoliposome carrying a plasmid vector driving expression of the human TP53 gene that encodes wild-type human p53. SGT-53 is currently in phase II human trials for advanced pancreatic cancer. Although p53 is best known as a tumor suppressor...

Descripción completa

Detalles Bibliográficos
Autores principales: Harford, Joe B., Kim, Sang Soo, Pirollo, Kathleen F., Chang, Esther H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027273/
https://www.ncbi.nlm.nih.gov/pubmed/35458469
http://dx.doi.org/10.3390/v14040739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027273/
https://www.ncbi.nlm.nih.gov/pubmed/35458469
http://dx.doi.org/10.3390/v14040739

Ejemplares similares